BioVie Inc/$BIVI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About BioVie Inc
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
- Ticker
- $BIVI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 13
- Headquarters
- Carson City, United States
- Website
- bioviepharma.com
BioVie Inc Metrics
BasicAdvanced
$17M
-
-$2.82
-
-
Price and volume
Market cap
$17M
52-week high
$3.79
52-week low
$0.82
Average daily volume
666K
Financial strength
Current ratio
2.402
Quick ratio
1.827
Long term debt to equity
0.024
Total debt to equity
0.039
Interest coverage (TTM)
-1,363.57%
Profitability
EBITDA (TTM)
-22.851
Management effectiveness
Return on assets (TTM)
-76.00%
Return on equity (TTM)
-143.66%
Valuation
Price to book
1.69
Price to tangible book (TTM)
1.79
Price to free cash flow (TTM)
-0.538
Free cash flow yield (TTM)
-185.86%
Free cash flow per share (TTM)
-2.36
Growth
Earnings per share change (TTM)
-60.14%
3-year earnings per share growth (CAGR)
-73.11%
BioVie Inc Financial Performance
Revenues and expenses
BioVie Inc Earnings Performance
Company profitability
Upcoming events
No upcoming events
BioVie Inc News
AllArticlesVideos
BioVie reports positive Phase 2 Parkinson's data for bezisterim
Proactive Investors3 weeks ago
BioVie says bezisterim eased fatigue and cognitive symptoms in Long COVID subgroups
Proactive Investors3 weeks ago
BioVie to present Long COVID and Parkinson's trial results at American Neurological Association meeting
Proactive Investors4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.